These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30224939)

  • 1. Coagulation Factor Plasma Levels Following Administration of a 4-Factor Prothrombin Complex Concentrate for Rapid Vitamin K Antagonist Reversal in Japanese Patients.
    Yasaka M; Brainsky A; Zhang P; Kushimoto S
    Curr Ther Res Clin Exp; 2018; 89():21-26. PubMed ID: 30224939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
    Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
    Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials.
    Milling TJ; Refaai MA; Sarode R; Lewis B; Mangione A; Durn BL; Harman A; Lee ML; Goldstein JN
    Acad Emerg Med; 2016 Apr; 23(4):466-75. PubMed ID: 26822172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
    Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
    Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study.
    Kushimoto S; Fukuoka T; Kimura A; Toyoda K; Brainsky A; Harman A; Chung T; Yasaka M
    Int J Hematol; 2017 Dec; 106(6):777-786. PubMed ID: 28815410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal.
    Refaai MA; Goldstein JN; Lee ML; Durn BL; Milling TJ; Sarode R
    Transfusion; 2015 Nov; 55(11):2722-9. PubMed ID: 26135740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma.
    Hood C; Goldstein JN; Milling TJ; Refaai MA; Bajcic P; Goldstein B; Sarode R
    Blood Adv; 2023 May; 7(10):2206-2213. PubMed ID: 36574241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding.
    Schick KS; Fertmann JM; Jauch KW; Hoffmann JN
    Crit Care; 2009; 13(6):R191. PubMed ID: 19948037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboembolic Events After Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate: Exploratory Analyses of Two Randomized, Plasma-Controlled Studies.
    Milling TJ; Refaai MA; Goldstein JN; Schneider A; Omert L; Harman A; Lee ML; Sarode R
    Ann Emerg Med; 2016 Jan; 67(1):96-105.e5. PubMed ID: 26094105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding.
    Go AS; Leong TK; Sung SH; Wei R; Harrison TN; Gupta N; Baker N; Goldstein B; Ataher Q; Solomon MD; Reynolds K;
    J Thromb Thrombolysis; 2022 Oct; 54(3):470-479. PubMed ID: 35984591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of Four-Factor Prothrombin Complex Concentrate in the Management of Critical Bleeding.
    Tanaka KA; Shettar S; Vandyck K; Shea SM; Abuelkasem E
    Transfus Med Rev; 2021 Oct; 35(4):96-103. PubMed ID: 34551881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
    Bitonti MT; Rumbarger RL; Absher RK; Curran LM
    J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy.
    Sobrino Jiménez C; Romero-Garrido JA; García-Martín Á; Quintana-Díaz M; Jiménez-Vicente C; González-Del Valle L; Herrero Ambrosio A; Benedí-González J
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e66-e71. PubMed ID: 32591479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-factor prothrombin complex concentrate versus plasma for urgent vitamin K antagonist reversal: new evidence.
    Sarode R
    Clin Lab Med; 2014 Sep; 34(3):613-21. PubMed ID: 25168946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total®, in anticoagulant reversal.
    Altorjay Á; Szabó É; Boda Z; Kramer L; Ngo LY; Engl W; Firth CL; Ahlstrom ER; Gelmont DM; Pabinger I
    Thromb Res; 2015 Mar; 135(3):485-91. PubMed ID: 25613927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis.
    Puchstein D; Kork F; Schöchl H; Rayatdoost F; Grottke O
    Thromb Haemost; 2023 Jan; 123(1):40-53. PubMed ID: 36626899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal: Does One Dose Fit All?
    Schwebach AA; Waybright RA; Johnson TJ
    Pharmacotherapy; 2019 May; 39(5):599-608. PubMed ID: 30892733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four factor prothrombin complex concentrate (human): review of the pharmacology and clinical application for vitamin K antagonist reversal.
    Kinard TN; Sarode R
    Expert Rev Cardiovasc Ther; 2014 Apr; 12(4):417-27. PubMed ID: 24650310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Safety and Effectiveness of a 4-Factor Prothrombin Complex Concentrate in Japanese Patients Experiencing Major Bleeding: A Post-marketing Surveillance Study.
    Yasaka M; Suzuki M; Kushimoto S; Kiyonaga A; Mangione A; Niwa Y; Terasaka N
    Cardiol Ther; 2024 Mar; 13(1):221-232. PubMed ID: 38319533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
    Le Roux P; Pollack CV; Milan M; Schaefer A
    J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.